Hancock Jaffe Laboratories ^{Priced, Nasdaq: HJLI}

We are a development stage medical device company developing biologic based solutions that are designed to be life-enhancing for patients with cardiovascular disease, peripheral arterial and venous disease and end-stage renal disease (ESRD). We are currently developing three bioprosthetic implantable devices for cardiovascular disease: the Bioprosthetic Heart Valve, the Bioprosthetic Coronary Artery Bypass Graft (CoreoGraft), and the Bioprosthetic Venous Valve (VenoValve). We have previously developed and obtained FDA pre-market approval for the ProCol Vascular Bioprosthesis, a product for hemodialysis in patients with ESRD, which we sold to LMAT in March 2016; our revenue stream is derived from the sub-contract manufacturing services and royalties earned on LMAT sales pursuant to the agreement with LMAT until 2019.